Open AccessImmunological Insights from Patients Undergoing Surgery on Ipilimumab for Metastatic Melanoma
Author(s) -
David Gyorki,
Jianda Yuan,
Zhenyu Mu,
Bushra Zaidi,
Melissa Pulitzer,
Klaus J. Busam,
Mary Sue Brady,
Daniel G. Coit,
James P. Allison,
Jedd D. Wolchok,
Charlotte E. Ariyan
Publication year - 2013
Publication title -
annals of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.764
H-Index - 173
eISSN - 1534-4681
pISSN - 1068-9265
DOI - 10.1245/s10434-013-2999-1
Subject(s) - ipilimumab , medicine , melanoma , foxp3 , surgical oncology , cd8 , immunotherapy , oncology , immune system , gastroenterology , surgery , cancer , immunology , cancer research
The tumor microenvironment after treatment with ipilimumab is not well described. Furthermore, the safety of surgery for patients being treated with ipilimumab for metastatic melanoma has not been well reported. This study analyzed the safety of surgery and the immune phenotype of tumors resected while on ipilimumab.